奥曲肽治疗顽固性Mallory-Weiss综合征24例  

Treatment of intractable Mallory-Weiss syndrome with octreotide:a report of 24 cases

作　　者：林海[1] 林志辉[1] 陈贻胜[1] 潘秀珍[1] 

机构地区：[1]福建医科大学省立临床医学院消化内科,福建省福州市350001

出　　处：《世界华人消化杂志》2009年第20期2117-2119,共3页World Chinese Journal of Digestology

摘　　要：目的:观察奥曲肽对顽固性Mallory-Weiss综合征(MWS)的疗效.方法:将经常规治疗24h仍出血不止的MWS患者47例,随机分为2组:治疗组(n=24)和对照组(n=23).对照组:单用静脉注射奥美拉唑40mg,每12h1次.治疗组:加用奥曲肽25μg/h微量泵泵入,连用3d.结果:治疗组加用奥曲肽治疗后,止血显效17例,占70.8%.治疗组总有效率(91.67%)明显优于对照组(73.91%),治疗组止血率明显优于对照组,差异有显著性(P<0.01).结论:对顽固性MWS大出血患者,常规治疗效果不佳时,加用奥曲肽治疗效果显著.AIM： To observe the efficacy of octreotide in the treatment of intractable Mallory-Weiss syndrome （MWS）. METHODS： Forty-seven MWS patients who did not respond to routine treatment within 24 h were randomly divided into two groups： treatment group （n = 24） and control group （n = 23）. Patients in the control group were given an intravenous infusion of 40 mg omeprazole, once every 12 hours, while those in the treatment group were given the same dose of omeprazole as well as continuous intravenous administration of octreotide via a micro pump at a constant speed of 25 μg/h for three days. RESULTS： After treatment with octreotide, hemostasis was achieved in 17 （70.8%） patients. The overall response rate achieved in the treatment group was significantly higher than that in the control group （91.67% vs 73.91%, P 〈 0.01）. Moreover, the hemostasis success rate in the treatment group was significantly higher than that in the control group （P 〈 0.01）. CONCLUSION： Combined use of octerotide and omeprazole is more effective in the treatment of MWS patients who do not respond to routine treatment.

关 键 词：奥曲肽 MALLORY-WEISS综合征 出血 

分 类 号：R573.2[医药卫生—消化系统] R735.8[医药卫生—内科学]